Clifford Capital Partners LLC Acquires 94,152 Shares of Pfizer Inc. (NYSE:PFE)

Clifford Capital Partners LLC boosted its stake in Pfizer Inc. (NYSE:PFE) by 21.3% during the 2nd quarter, HoldingsChannel reports. The fund owned 536,745 shares of the biopharmaceutical company’s stock after acquiring an additional 94,152 shares during the quarter. Pfizer comprises 3.3% of Clifford Capital Partners LLC’s investment portfolio, making the stock its 13th largest position. Clifford Capital Partners LLC’s holdings in Pfizer were worth $15,018,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. Capital International Ltd. CA grew its stake in shares of Pfizer by 2.2% during the 4th quarter. Capital International Ltd. CA now owns 371,336 shares of the biopharmaceutical company’s stock worth $10,691,000 after acquiring an additional 7,991 shares in the last quarter. Capital International Sarl boosted its stake in shares of Pfizer by 9.3% during the 4th quarter. Capital International Sarl now owns 438,138 shares of the biopharmaceutical company’s stock worth $12,614,000 after buying an additional 37,233 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Pfizer by 283.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 705,479 shares of the biopharmaceutical company’s stock valued at $20,311,000 after acquiring an additional 521,677 shares in the last quarter. Crossmark Global Holdings Inc. increased its position in shares of Pfizer by 1.4% in the fourth quarter. Crossmark Global Holdings Inc. now owns 78,863 shares of the biopharmaceutical company’s stock valued at $2,271,000 after acquiring an additional 1,107 shares during the last quarter. Finally, Morningstar Investment Management LLC boosted its position in Pfizer by 4.8% during the fourth quarter. Morningstar Investment Management LLC now owns 37,016 shares of the biopharmaceutical company’s stock valued at $1,066,000 after purchasing an additional 1,710 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. UBS Group upped their price objective on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Barclays lifted their price objective on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Wells Fargo & Company raised their target price on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday, September 16th. Nine equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Stock Down 0.9 %

PFE stock opened at $28.67 on Wednesday. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $34.11. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The stock has a market capitalization of $162.46 billion, a price-to-earnings ratio of -477.83, a PEG ratio of 1.27 and a beta of 0.68. The business’s fifty day moving average price is $29.28 and its two-hundred day moving average price is $28.31.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same period last year, the firm earned $0.67 earnings per share. Pfizer’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, equities analysts anticipate that Pfizer Inc. will post 2.66 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.